We are thrilled to congratulate S1P Therapeutics Inc. on receiving a prestigious Virginia Catalyst grant to support their innovative research into treatments for kidney and autoimmune diseases. This recognition underscores the impactful work of S1P Therapeutics and their commitment to improving the lives of patients suffering from Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD).
S1P Therapeutics is pioneering a novel therapeutic target by blocking Spns2-dependent S1P transport to address kidney disease. In collaboration with researchers from Virginia Tech and the University of Virginia, S1P Therapeutics will use the $800,000 Catalyst funding to advance their experimental drugs toward clinical applications.
The company’s work addresses critical health challenges—AKI impacts nearly one-third of patients undergoing cardiac surgery and is a major risk factor for CKD, which affects 37 million people in the U.S. Many individuals with early-stage CKD remain undiagnosed, making this research especially important.
We are proud to support companies like S1P Therapeutics that are making strides in advancing healthcare and offering hope to those affected by kidney disease. We look forward to their continued progress and the positive impact their work will have on the medical community.
About S1P Therapeutics Inc:
Based at VTCRC in Blacksburg, VA, S1P Therapeutics is focused on developing novel therapies to treat kidney diseases, offering potential solutions to improve outcomes for those suffering from AKI and CKD.